Çakar Burcu, Sürmeli Zeki, Öner Pınar Gürsoy, Yelim Elif Sıla, Karabulut Bülent, Uslu Ruchan
Division of Medical Oncology, Tülay Aktaş Oncology Hospital, Ege University School of Medicine, İzmir, Turkey.
Division of Medical Oncology, Medical Park Hospital, Ankara,Turkey.
Eur J Breast Health. 2018 Oct 1;14(4):211-217. doi: 10.5152/ejbh.2018.4170. eCollection 2018 Oct.
Inflammatory breast cancer (IBC) has an unfavourable prognosis despite the advances made in the treatment of breast cancer. Our study aimed to define immunohistochemistry-based surrogate subtype distribution to determine whether the breast cancer subtype accompanied survival outcome differences in IBC.
Medical records of female breast cancer patients with non-metastatic inflammatory breast cancer admitted to our clinic between March 2000 and December 2015 were retrospectively reviewed. Patient demographics, clinical and pathological feature of the primary tumour, adjuvant treatment options and survival data were analysed. Intrinsic breast cancer subtypes were defined according to ER, PR, HER-2 and ki-67 status.
We identified 129 non-metastatic inflammatory breast cancer patients. Median follow-up was 73 months. 10 (7.7%) were luminal A-like, 67 (51.9%) were luminal B-like, 37 (28.6%) were HER-2 positive, and 15 (11.6%) were triple negative (TNBC) by immunohistochemistry. There were no statistically significant differences between subtypes in terms of histological type, grade, tumour size and lymph node status. Median disease-free survival was 47 months (95% confidence interval [CI] 29.2-82.6) and median overall survival was 75 months (95% CI 64.7-90.8). Triple negative breast cancer showed poorer outcome than other subgroups. Presence of TNBC disease was associated with poorer outcome compared to luminal A (HR: 0.19, 95% CI 0.04-0.92, p: 0.039), luminal B (HR: 0.34, 95% CI 0.15-0.74, p: 0.007) and HER-2 positive subgroups (HR: 0.40, 95% CI 0.17-0.94, p:0.037). Luminal A patients had a trend to have a better overall survival which did not reach to a statistical significant difference.
Our study put forth that IBC have a poor prognosis irrespective of breast cancer surrogate subtype distribution. Luminal A, the most frequent subtype of breast cancer was the least common in our IBC patient group. TNBC had the worst outcome when compared to other breast cancer subtypes.
尽管乳腺癌治疗取得了进展，但炎性乳腺癌（IBC）的预后仍不理想。我们的研究旨在确定基于免疫组织化学的替代亚型分布，以确定乳腺癌亚型是否伴随IBC患者生存结果的差异。
回顾性分析2000年3月至2015年12月间我院收治的非转移性炎性乳腺癌女性患者的病历。分析患者的人口统计学资料、原发性肿瘤的临床和病理特征、辅助治疗方案及生存数据。根据雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体2（HER-2）和Ki-67状态定义原发性乳腺癌亚型。
我们共纳入129例非转移性炎性乳腺癌患者。中位随访时间为73个月。免疫组织化学结果显示，10例（7.7%）为腔面A型，67例（51.9%）为腔面B型，37例（28.6%）为HER-2阳性，15例（11.6%）为三阴性（TNBC）。各亚型在组织学类型、分级、肿瘤大小及淋巴结状态方面无统计学显著差异。中位无病生存期为47个月（95%置信区间[CI]29.2 - 82.6），中位总生存期为75个月（95%CI 64.7 - 90.8）。三阴性乳腺癌的预后较其他亚组差。与腔面A型（风险比：0.19，95%CI 0.04 - 0.92，p：0.039）、腔面B型（风险比：0.34，95%CI 0.15 - 0.74，p：0.007）和HER-2阳性亚组（风险比：0.40，95%CI 0.17 - 0.94，p：0.037）相比，TNBC疾病的存在与较差的预后相关。腔面A型患者总体生存期有更好的趋势，但未达到统计学显著差异。
我们的研究表明，无论乳腺癌替代亚型分布如何，IBC的预后都很差。腔面A型是乳腺癌最常见的亚型，但在我们的IBC患者组中最不常见。与其他乳腺癌亚型相比，TNBC的预后最差。
